Navigation Links
Nektar Therapeutics to Webcast R&D Day on November 12th
Date:10/27/2008

SAN CARLOS, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced that it will host an R&D Day for investors and analysts at the InterContinental Hotel in New York on Wednesday, November 12, 2008, beginning at 12:00 p.m. Eastern Time. The webcast portion of this event will conclude at approximately 3:30 p.m.

Nektar's R&D Day will consist of a series of presentations and Q&A related to the Company's clinical development programs, key research and development, and industry-leading PEGylation and conjugate chemistry-based drug development platform.

The presentations and Q&A sessions will be accessible via a live audio and slideshow webcast through a link on the Nektar homepage, http://www.nektar.com. The webcast will be available for replay until November 26, 2008.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and conjugate chemistry technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.

Stephan Herrera, 415-488-7699

sherrera@nektar.com

Jennifer Ruddock, 650-631-4954

jruddock@nektar.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
2. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
3. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
4. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
5. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
6. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
7. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
8. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
9. West Concludes Agreement with Nektar
10. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
11. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... Opal Kelly, a leading ... PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB ... sized form factor suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
(Date:1/18/2017)... 2017   Parent Project Muscular Dystrophy (PPMD) , ... Duchenne muscular dystrophy (Duchenne) , today announced a $600,000 ... of Technology (NJIT) and Talem Technologies (Talem) as part ... to assist people living with Duchenne. PPMD is ... an embedded computer, software, a force sensor and a ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took place ... in Valley Stream, NY. The procedure was an anterior cervical discectomy and fusion ...
Breaking Biology Technology:
(Date:12/22/2016)... December 22, 2016 SuperCom (NASDAQ: ... solutions for the e-Government, Public Safety, HealthCare, and Finance sectors announced ... has been selected to implement and deploy a community-based supportive services ... Northern California , further expanding its presence in the state. ... This new program, ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
(Date:12/16/2016)... 2016 The global wearable medical device market, in terms ... from USD 5.31 billion in 2016, at a CAGR of 18.0% ... ... advancements in medical devices, launch of a growing number of smartphone-based ... among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):